Singh said ”Mission COVID Suraksha – The Indian COVID-19 vaccine development mission” is being implemented at a total cost of Rs 900 crore. The mission is supporting the development of COVID-19 vaccine candidates (5), facilities for animal challenge studies (3), facilities for immunogenicity assays (3), clinical trial sites (19).
Category:
Pandemic
Latest
62.54% Covid vaccination registrations done on-site, 77% jabs given in walk-in mode, says govt
Union Health Minister Mansukh Mandaviya in a written reply said the Co-WIN system is an inclusive platform designed keeping in mind the limitations and challenges posed due to the extent of digital literacy and lack of access to digital devices in some areas.
All necessary features to ensure that every eligible individual has access to vaccination, regardless of physical, digital, or socioeconomic barriers have been incorporated in Co-WIN, he said.
Increased risk of heart attack, stroke in first two weeks following Covid: Lancet study
“The results indicate that acute cardiovascular complications represent an important clinical manifestation of COVID-19,” said Ioannis Katsoularis from Umea University, a co-author of the study.
“Our results also show how important it is to vaccinate against COVID-19, in particular the elderly who are at increased risk of acute cardiovascular events,” Katsoularis said.
COVID-19 controls turn Asia into global surveillance hotspot, analysts say
“Asia as a region risks sleep-walking into serious privacy breaches if there isn’t transparency when it comes to data use with respect to COVID-19 surveillance measures,” said Sofia Nazalya, a human rights analyst at Verisk Maplecroft.
No clear link between school opening and COVID surge, study finds
IfE found that 52 countries that sent students back to school in August and September – including France and Spain – saw infection rates rise during the vacation compared to when they were closed.
In Britain and Hungary, however, infection levels dropped after initial school closures, remained low during the holidays, and began rising after reopening.
The vast majority – 92% – of countries that are through their first wave of COVID-19 infections have started to reopen school systems, even as some are seeing a second surge.
Push to bring coronavirus vaccines to the poor faces trouble
In one of the biggest obstacles, rich countries have locked up most of the world’s potential vaccine supply through 2021, and the U.S. and others have refused to join the project, called Covax.
The supply of vaccines is not going to be there in the near term, and the money also isn’t there, warned Rohit Malpani, a public health consultant who previously worked for Doctors Without Borders.
Risk aversion sets in after Trump tests positive for coronavirus
Taking to Twitter, he wrote, “Tonight, @FLOTUS and I tested positive for Covid-19. We will begin our quarantine and recovery process immediately. We will get through this together.
India’s coronavirus infections rise to 6.39 million
Deaths from coronavirus infections rose by 1,095 in the last 24 hours to 99,773, the ministry said.The total recoveries have surged to 53,52,078. There are 9,42,217 active cases of coronavirus infection in the country which comprises 14.74 per cent of the total caseload, the data stated.The COVID-19 case fatality rate was recorded at 1.56 per cent
Unlock5: Centre permits schools, colleges, cinemas to reopen from October 15
However, the ministry said that restrictions on international travel, except those permitted by the Centre, will continue. Swimming pools being used for training of sportspersons will be allowed to open for which the standard operating procedure (SOP) will be issued by the Ministry of Youth Affairs and Sports.
The lockdown shall continue to be implemented strictly in the containment zones till October 31, the ministry said. The home ministry reiterated that states will not impose any local lockdown outside the containment zones without prior consultation with the central government. There will be no restriction on inter-state and intra-state movement.
Lloyd’s launches “first-of-its-kind” parametric business interruption insurance policy for SMEs
Parametrix Insurance offers simple and reliable coverage by removing the traditional indemnity trigger that most insurance policies today use. Instead, the new solution uses a parametric trigger, meaning that the policy automatically pays out if a customer’s critical IT services – such as cloud, e-commerce or payment systems – are disrupted. This significantly reduces the time insurers spend assessing a loss or adjusting a claim.
The new product is led by Tokio Marine Kiln (TMK) and supported by other members of Lloyd’s Product Innovation Facility including RenaissanceRe. It is the first off-the-shelf parametric IT downtime policy tailored towards SMEs.
Moderna COVID-19 vaccine appears safe, shows signs of working in older adults: study
The findings are reassuring because immunity tends to weaken with age, Dr. Evan Anderson, one of the study’s lead researchers from Emory University in Atlanta, said in a phone interview.
India’s coronavirus infections rise to 6.31 million
Deaths from coronavirus infections rose by 1,181 to 98,678, the ministry said.Reported active COVID-19 cases in India now stand at 9,40,705. As many as 52,73,201 COVID-19 patients have been cured and discharged so far, the Union Health Ministry has said in its latest update.
AstraZeneca gets partial immunity in low-cost EU vaccine deal
Drugmakers have called on EU regulators to set up a Europe-wide compensation scheme, while patients’ organizations are calling for an EU-wide fund financed by pharmaceutical firms that would compensate for unexpected side-effects.
The EU legal regime is among the least favorable to drugmakers on compensation claims, although plaintiffs have rarely managed to win as the law requires them to prove the link between an illness and a vaccine that may have caused it.
The United States has granted immunity from liability for COVID-19 vaccines that receive regulatory approval. Meanwhile, Russia has said it would shoulder some of the legal liability should anything go wrong with the vaccine developed by Moscow’s Gamaleya Institute.